817 results match your criteria: "Hypersomnia Primary"
Residual hypersomnia in unipolar and bipolar depression: A systematic review.
World J Biol Psychiatry
December 2024
Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Article Synopsis
- - The study aims to address the ongoing symptoms of depression, particularly focusing on residual hypersomnia, which significantly impacts daily life and is under-researched.
- - A systematic review analyzed data from multiple databases to assess the prevalence and treatment options for residual hypersomnia in depression, finding that current treatments, including modafinil and CPAP for patients with sleep apnea, show limited long-term effectiveness.
- - The research highlights challenges like unclear definitions and a lack of rigorous trials, emphasizing the need for more studies to improve the understanding and management of residual hypersomnia in depressed patients.
Efficacy and safety of sodium oxybate treatment in adults with narcolepsy and cataplexy: a systematic review and meta-analysis.
Sleep Breath
November 2024
Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Article Synopsis
- Narcolepsy is a chronic condition marked by excessive daytime sleepiness and cataplexy, and sodium oxybate (SXB) has been identified as the only effective treatment for its symptoms.
- The study reviewed five randomized controlled trials (RCTs) to evaluate the effectiveness of SXB in reducing cataplexy attacks and improving wakefulness while also considering its safety by monitoring adverse events.
- Results showed that SXB significantly reduced weekly cataplexy attacks and improved outcomes on various tests compared to placebo, particularly at higher doses, indicating it is an effective treatment for managing narcolepsy symptoms with a reasonably safe profile.
Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.
Cochrane Database Syst Rev
November 2024
Departement de Biostatistique et Informatique Médicale, Hôpital Saint Louis, 75475 Paris, France.
Article Synopsis
- Excessive daytime sleepiness is a frequent issue in myotonic dystrophy, prompting the use of psychostimulants to treat hypersomnia in these patients.
- The study aimed to evaluate the effectiveness of psychostimulants in alleviating hypersomnia symptoms in individuals with myotonic dystrophy, using data from randomized controlled trials.
- A total of six trials involving 136 adult participants were reviewed, suggesting a positive short-term impact of psychostimulants on improving wakefulness, with most trials showing low risk of bias.
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Sleep Med
December 2024
Bogan Sleep Consultants, LLC, Columbia, SC, USA.
Narcolepsy is a rare, chronic neurological disorder characterized by a dysregulated sleep-wake cycle, with core clinical features including excessive daytime sleepiness (EDS), cataplexy, hypnopompic/hypnagogic hallucinations, and sleep paralysis. Several treatment options are available for the symptomatic management of narcolepsy, but they have limitations. Comorbidities of narcolepsy further limit the treatment choices.
View Article and Find Full Text PDFRegulation of wakefulness by neurotensin neurons in the lateral hypothalamus.
Exp Neurol
January 2025
Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Division of Sleep Medicine, Harvard Medical School, Boston, MA, United States of America. Electronic address:
Article Synopsis
- The lateral hypothalamic region (LH) is important for regulating arousal, but the exact types of cells and mechanisms involved are still unclear.
- Orexin (OX) neurons are known for promoting wakefulness, but their absence doesn't stop wakefulness, indicating there are other wake-promoting cells.
- Recent research uncovered neurotensin (Nts) neurons in the LH that significantly enhance wakefulness; disrupting these cells reduced wakeful periods and increased sleepiness in mice, highlighting their key role in maintaining arousal.
Hypnosis: An aid in working with patients with narcolepsy.
Am J Clin Hypn
November 2024
Valley Mount Sinai Children's Health, Paramus, New Jersey, USA.
Article Synopsis
- - Narcolepsy is a neurological sleep disorder marked by excessive daytime sleepiness and cataplexy, affecting about 1 in 2000 people, and can occur at any age, not just in adults.
- - It often mimics other mental health conditions like anxiety or ADHD in children and young adults, which can delay proper diagnosis and treatment.
- - In addition to standard medications, clinical hypnosis shows promise in helping young patients manage their symptoms and reduce medication side effects by gaining better control over sleepiness and emotional triggers for cataplexy.
Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.
BMJ Open
October 2024
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China
Article Synopsis
- Zanubrutinib, a second-generation Bruton's tyrosine kinase inhibitor, is being studied for its adverse effects based on real-world data from the FDA’s AE Reporting System between 2019-2023.
- A comprehensive analysis identified 846 AE reports related to zanubrutinib, revealing 74 positive signals across various organ systems, with key issues in blood disorders and significant signals like 'haemorrhage subcutaneous'.
- The study indicates that switching from monotherapy to combination therapy with rituximab or chemotherapy escalates the risk of serious adverse events, with some unexpected off-label AEs also noted, such as skin discoloration and cardiac arrest.
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (iSPHYNCS): the impact of psychiatric comorbidities on daily life in central disorders of hypersomnolence-a vicious circle.
J Sleep Res
October 2024
Department of Neurology, Center for Sleep Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Article Synopsis
- The study investigates the frequency of psychiatric disorders in patients with narcolepsy type-1 (NT1) and other central disorders of hypersomnolence (OCH), finding that 38 out of 90 patients (27% of NT1 and 48% of OCH) had at least one psychiatric issue.
- Major depressive episodes and suicidality were the most common psychiatric conditions observed, with a notable prevalence among females.
- Those with psychiatric comorbidities experienced more severe fatigue, apathy, disturbed sleep, and poorer overall quality of life, indicating a negative impact on their daily functioning due to the combination of these disorders and hypersomnolence symptoms.
Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.
Brain Behav Immun Health
November 2024
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Belgium.
Article Synopsis
- The immune system plays a crucial role in major depressive disorder (MDD), with about 30% of depressed patients exhibiting inflammation and atypical symptoms, leading to a poorer response to standard antidepressants.
- The INSTA-MD trial is a 12-week, double-blind study assessing the effectiveness of minocycline or celecoxib as adjunct treatments for patients with MDD who have not responded to previous antidepressant trials.
- The trial will stratify participants based on their inflammation levels (high vs. low hsCRP) and aims to determine if this stratification can help predict treatment response and improve outcomes with these immune-targeted therapies.
Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial.
Sleep Med
December 2024
Avadel Pharmaceuticals, Chesterfield, MO, USA. Electronic address:
Article Synopsis
- Extended-release sodium oxybate (ON-SXB) showed significant improvements in narcolepsy symptoms in the REST-ON trial, which was a phase 3 study comparing it to a placebo.
- This analysis looked at the effectiveness of ON-SXB in patients both with and without the use of other alerting medications.
- Results indicated that ON-SXB led to substantial improvements in sleep latency, cataplexy episodes, and overall sleepiness, regardless of whether participants were using alerting agents.
Rest-Activity Rhythm Phenotypes in Adults with Epilepsy and Intellectual Disability.
medRxiv
September 2024
Departments of Neurology, Neuroscience and Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX USA.
Article Synopsis
- The study investigates how sleep and rest-activity rhythms (RARs) are disrupted in adults with epilepsy and intellectual disability (E+ID) using wrist actigraphy to measure these patterns.
- Primary caregivers completed surveys that assessed epilepsy severity, adaptive functioning, and psychopathology while ensuring subjects wore an actigraphy device for at least ten days.
- Results showed that E+ID subjects had lower RAR amplitude, robustness, and stability compared to adults with epilepsy without intellectual disability and matched intellectually capable individuals.
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial.
CNS Drugs
November 2024
Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA.
Article Synopsis
- The study aimed to compare the effectiveness of modafinil versus amphetamine-dextroamphetamine in treating narcolepsy type 2 and idiopathic hypersomnia through a randomized, blinded trial involving 44 adults over 12 weeks.
- Results showed that while modafinil improved sleepiness levels (5.0 points on the Epworth scale) more than amphetamine-dextroamphetamine (4.4 points), the latter was noninferior in several secondary measures of symptoms and disease severity.
- Adverse effects were more prevalent with modafinil, including higher rates of anxiety, while amphetamine-dextroamphetamine showed less dropouts due to adverse events, suggesting implications for treatment choices in these disorders.
Excessive daytime sleepiness in obstructive sleep apnea: Indirect treatment comparison of wake-promoting agents in patients adherent/nonadherent to primary OSA therapy.
Sleep Med Rev
December 2024
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. Electronic address:
Article Synopsis
- * The study analyzed 18 research articles and found that all four WPAs significantly improved sleepiness levels according to the Epworth Sleepiness Scale (ESS) and maintenance of wakefulness test (MWT), with rankings suggesting solriamfetol as the most effective.
- * In terms of side effects, solriamfetol had the lowest overall discontinuation rates, while pitolisant showed minimal adverse events, indicating
Sleep disorder syndromes of post-acute sequelae of SARS-CoV-2 (PASC) / Long Covid.
Sleep Med
November 2024
Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, United States. Electronic address:
Article Synopsis
- COVID-19 can lead to a condition called post-acute sequelae of SARS-CoV-2 (PASC), or "Long COVID," which commonly includes various sleep disturbances such as insomnia and excessive daytime sleepiness.
- A study involving patients from the Covid Survivorship Program evaluated sleep disorders, resulting in diagnoses like obstructive sleep apnea, chronic insomnia, and REM behavior disorder among others.
- The findings suggest that specific sleep issues are prevalent in individuals with PASC, highlighting the need for thorough sleep assessments for those experiencing severe sleep problems after COVID-19 infection.
Association of Snoring and Daytime Sleepiness With Subsequent Incident Hypertension: A Population-Based Cohort Study.
Hypertension
November 2024
Université Paris Cité, Paris Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Service 011 Population-based Cohorts Unit, France (P.B., S.K., M.G., M.Z., E.W.).
Article Synopsis
- A study was conducted to explore the relationship between snoring, daytime sleepiness, and the risk of developing hypertension among normotensive individuals aged 18 to 69 in France.* -
- Out of nearly 35,000 participants, those who reported habitual snoring and excessive daytime sleepiness had a higher incidence of treated hypertension during a follow-up period of about 3.1 years.* -
- The findings suggest that regular snoring and daytime sleepiness could serve as useful indicators for hypertension risk, indicating that screening for these symptoms might help in preventing high blood pressure.*
[Sleep disorders in patients with medication-overuse headache].
Zh Nevrol Psikhiatr Im S S Korsakova
June 2024
Ural State Medical University, Yekaterinburg, Russia.
Article Synopsis
- The study investigates sleep disorders in patients with medication-overuse headache (MOH) versus those without MOH, analyzing their prevalence and severity using established scales.
- Conducted with 171 MOH patients and 173 control patients, results showed that MOH patients have a higher prevalence of sleep-related issues, especially chronic insomnia and restless legs syndrome.
- Findings highlight the importance of addressing sleep disorders in patients with MOH, suggesting they may play a significant role in the overall condition and treatment of these patients.
Impact of excessive daytime sleepiness on attention impairment in obstructive sleep apnea: a cross-sectional observational study.
Eur Arch Otorhinolaryngol
October 2024
Department of Respiratory and Critical Care Medicine, Sleep Center, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
Article Synopsis
- This study investigates how excessive daytime sleepiness (EDS) affects attention in Chinese patients with obstructive sleep apnea (OSA), focusing on a sample of 1996 individuals.
- The findings reveal that patients with EDS tend to have higher body mass index (BMI) and more serious health conditions, along with lower quality of sleep and oxygen levels, although overall cognitive test scores were similar between those with and without sleepiness.
- Notably, the results indicate that education level significantly influences attention impairment, especially in patients younger than 40, while those aged 40 and above show a stronger connection between attention deficits, education, age, and severity of OSA.
Narcolepsy and risk of traumatic injury: a population-based matched cohort study.
J Clin Sleep Med
October 2024
Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Article Synopsis
- A study analyzed the risk of traumatic injuries and fractures in patients with narcolepsy compared to the general population, using a large Japanese health insurance database.
- Researchers followed 2,451 narcolepsy patients and 10,591 matched individuals for up to 5 years, finding that those with narcolepsy had significantly higher rates of injuries (11.4 vs. 6.2 per 100 person-years) and fractures (2.3 vs. 1.3 per 100 person-years).
- The study concluded that narcolepsy increases the risk of traumatic injuries, suggesting the need for preventive measures specifically for these patients.
Development of a mindfulness-based intervention for narcolepsy: a feasibility study.
Sleep
October 2024
Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Article Synopsis
- - The study explored the feasibility and acceptability of a mindfulness-based intervention (MBI) specifically adapted for adults with narcolepsy, comparing three different program lengths: 4-week, 8-week, and 12-week.
- - Results showed that a significant number of participants met benchmarks for attendance, meditation practice, and data collection, with higher success rates in the brief and extended groups compared to the standard group.
- - All groups reported improvements in mindfulness, self-compassion, psychosocial functioning, and mood, with the extended MBI showing the best clinical outcomes, suggesting a viable approach for future narcolepsy treatments.
Insomnia Symptoms Are Associated with Measures of Functional Deterioration and Dementia Status in Adults with Down Syndrome at High Risk for Alzheimer's Disease.
J Alzheimers Dis
July 2024
Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA.
Article Synopsis
- A study investigates the relationship between obstructive sleep apnea (OSA) and insomnia symptoms with Alzheimer's disease (AD) in adults with Down syndrome (DS), highlighting the need for more research in this area.
- Findings show that older women with DS who have dementia experience more severe insomnia symptoms compared to those without dementia, but OSA symptoms do not differ significantly.
- The results suggest that treating insomnia symptoms could be crucial for improving daily living activities and slowing the progression of dementia in adults with DS.
Prevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial.
Trials
May 2024
Department of Anesthesia and Pain Medicine, University of Toronto, Toronto, ON, Canada.
Article Synopsis
- * A multicenter clinical trial called PLAN will study the effects of intravenous lidocaine versus a placebo in over 1,600 patients undergoing breast cancer surgery, measuring outcomes like persistent pain incidence and opioid use at various time points post-surgery.
- * If successful, the trial could establish lidocaine infusion as a standard treatment to reduce chronic pain and opioid reliance in breast cancer patients, potentially lowering healthcare costs and improving overall patient well-being.
A case of accidental self-enucleation caused by obstructive sleep apnea.
J Clin Sleep Med
August 2024
Minnesota Regional Sleep Disorders Center, and Departments of Neurology, Hennepin County Medical Center and University of Minnesota Medical School, Minneapolis, Minnesota.
Article Synopsis
- A 55-year-old woman with obstructive sleep apnea (OSA) and obesity hypoventilation syndrome experienced severe injuries after suddenly falling asleep and colliding with a sharp object, leading to the surgical removal of her right eye.
- The study reviews existing literature on injuries related to OSA, including falls and motor vehicle accidents, while highlighting the risks associated with excessive daytime sleepiness.
- The authors stress the importance of educating healthcare providers on the early detection and treatment of OSA to prevent such serious injuries.
Prevalence of major depressive disorder and post-traumatic stress disorder among first-time sleep center attendees.
Sleep Med
July 2024
Department of Respiratory and Sleep Medicine, Angers University hospital, Angers, France; INSERM, CNRS, MITOVASC, University of Angers, Angers, France.
Article Synopsis
- Sleep disorders and psychiatric conditions, like major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), are closely linked, with sleep complaints frequently observed in those suffering from these psychiatric issues.
- A study involving 755 patients at a sleep clinic found that a notable percentage of patients had positive screenings for MDD (12.1%) and PTSD (4.9%), especially among those seeking help for insomnia.
- The results highlight the need for routine psychiatric screenings in sleep clinics, as many patients with positive MDD or PTSD screenings were not receiving appropriate treatment, emphasizing the importance of addressing these coexisting conditions.
Narcolepsy: an interface among neurology, immunology, sleep, and genetics.
Arq Neuropsiquiatr
June 2024
Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.
Article Synopsis
- - Narcolepsy, a central nervous system disorder, is characterized by excessive daytime sleepiness and symptoms like cataplexy and sleep paralysis, primarily caused by a genetic-immune interaction leading to hypocretin-1 deficiency, especially in type I.
- - There is a significant delay in diagnosis, often exceeding ten years, and patients often experience various comorbidities that negatively affect their quality of life.
- - Effective treatment requires education for patients and their circles, incorporating scheduled naps and sleep hygiene, with advancements in medications like stimulants and orexin agonists, highlighting the need for better awareness of this rare condition.